MX2021007835A - Polipeptidos utiles para edicion de genes y metodos de uso. - Google Patents

Polipeptidos utiles para edicion de genes y metodos de uso.

Info

Publication number
MX2021007835A
MX2021007835A MX2021007835A MX2021007835A MX2021007835A MX 2021007835 A MX2021007835 A MX 2021007835A MX 2021007835 A MX2021007835 A MX 2021007835A MX 2021007835 A MX2021007835 A MX 2021007835A MX 2021007835 A MX2021007835 A MX 2021007835A
Authority
MX
Mexico
Prior art keywords
interest
target sequence
binding
crispr
compositions
Prior art date
Application number
MX2021007835A
Other languages
English (en)
Spanish (es)
Inventor
Michael Lassner
Mark Moore
Tyson D Bowen
Tedd D Elich
Alexandra Briner Crawley
Rodolphe Barrangou
Original Assignee
Lifeedit Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lifeedit Therapeutics Inc filed Critical Lifeedit Therapeutics Inc
Publication of MX2021007835A publication Critical patent/MX2021007835A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04004—Adenosine deaminase (3.5.4.4)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MX2021007835A 2018-12-27 2019-12-20 Polipeptidos utiles para edicion de genes y metodos de uso. MX2021007835A (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201862785391P 2018-12-27 2018-12-27
US201962790261P 2019-01-09 2019-01-09
US201962790256P 2019-01-09 2019-01-09
US201962790262P 2019-01-09 2019-01-09
US201962790266P 2019-01-09 2019-01-09
US201962790258P 2019-01-09 2019-01-09
US201962932169P 2019-11-07 2019-11-07
PCT/US2019/068079 WO2020139783A2 (en) 2018-12-27 2019-12-20 Polypeptides useful for gene editing and methods of use

Publications (1)

Publication Number Publication Date
MX2021007835A true MX2021007835A (es) 2021-08-11

Family

ID=69182752

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021007835A MX2021007835A (es) 2018-12-27 2019-12-20 Polipeptidos utiles para edicion de genes y metodos de uso.

Country Status (14)

Country Link
US (4) US12655426B2 (cg-RX-API-DMAC7.html)
EP (2) EP4339286A3 (cg-RX-API-DMAC7.html)
JP (3) JP7572360B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210149686A (cg-RX-API-DMAC7.html)
CN (1) CN113631704A (cg-RX-API-DMAC7.html)
AU (2) AU2019416108B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021012665A2 (cg-RX-API-DMAC7.html)
ES (1) ES2970169T3 (cg-RX-API-DMAC7.html)
IL (2) IL284400B1 (cg-RX-API-DMAC7.html)
MX (1) MX2021007835A (cg-RX-API-DMAC7.html)
SG (1) SG11202106977PA (cg-RX-API-DMAC7.html)
TW (1) TW202039847A (cg-RX-API-DMAC7.html)
WO (1) WO2020139783A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA202105281B (cg-RX-API-DMAC7.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019282149B2 (en) * 2018-06-05 2025-08-21 Life Edit Therapeutics, Inc. RNA-guided nucleases and active fragments and variants thereof and methods of use
CN118813654A (zh) 2019-08-12 2024-10-22 生命编辑制药股份有限公司 Rna指导的核酸酶及其活性片段及变体以及使用方法
JP2023516226A (ja) 2020-04-24 2023-04-18 ライフエディット セラピューティクス,インコーポレイティド Rna誘導型ヌクレアーゼとその活性な断片およびバリアント、ならびに利用の方法
CN116194581A (zh) 2020-07-01 2023-05-30 艾勒维生技公司 使用环状rna进行细胞重编程的组合物和方法
JP7890972B2 (ja) * 2020-07-15 2026-07-15 ライフ エディット セラピューティクス,インコーポレイティド ウラシル安定化タンパク質並びにその活性断片及びバリアント並びに使用方法
EP4211235A2 (en) 2020-09-11 2023-07-19 Lifeedit Therapeutics, Inc. Dna modifying enzymes and active fragments and variants thereof and methods of use
CA3173950A1 (en) * 2021-03-22 2022-09-22 Tyson D. BOWEN Dna modifyng enzymes and active fragments and variants thereof and methods of use
CN117729931A (zh) * 2021-05-14 2024-03-19 比姆医疗股份有限公司 用于治疗转甲状腺素蛋白淀粉样变性的组合物和方法
MX2023014774A (es) * 2021-06-11 2024-01-15 Bayer Ag Nuevos sistemas de endonucleasas programables de arn tipo v.
EP4101928A1 (en) * 2021-06-11 2022-12-14 Bayer AG Type v rna programmable endonuclease systems
CA3173953A1 (en) 2021-06-11 2023-12-10 Tyson D. BOWEN Rna polymerase iii promoters and methods of use
WO2023031856A1 (en) 2021-09-02 2023-03-09 Sanofi Compositions and methods for rna affinity purification
KR20240065326A (ko) 2021-10-05 2024-05-14 사노피 지질 나노입자(lnp)를 냉동 및 냉동-건조하는 방법 및 이를 사용하여 수득된 lnp
EP4453191A1 (en) * 2021-12-23 2024-10-30 Bayer Aktiengesellschaft Novel small type v rna programmable endonuclease systems
JP2025504430A (ja) 2022-01-17 2025-02-12 サノフイ 脂質化合物及びその使用
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
JP2025504898A (ja) 2022-01-24 2025-02-19 ライフエディット セラピューティクス,インコーポレイティド Rna誘導型ヌクレアーゼ及びその活性断片及びバリアント、並びに使用方法
CN119421716A (zh) 2022-06-17 2025-02-11 赛诺菲 用于环状rna亲和纯化的组合物和方法
JP2025525569A (ja) 2022-07-18 2025-08-05 レナゲード セラピューティクス マネージメント インコーポレイテッド 遺伝子編集成分、システム、及び使用方法
AU2023323547A1 (en) 2022-08-12 2025-03-20 Life Edit Therapeutics, Inc. Rna-guided nucleases and active fragments and variants thereof and methods of use
WO2024042489A1 (en) 2022-08-25 2024-02-29 LifeEDIT Therapeutics, Inc. Chemical modification of guide rnas with locked nucleic acid for rna guided nuclease-mediated gene editing
AU2023329392A1 (en) 2022-08-25 2025-02-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
IL320573A (en) 2022-11-04 2025-07-01 Life Edit Therapeutics Inc Developed adenine deaminases and RNA-guided nuclease fusion proteins with internal insertion sites and methods of use
CN117327679B (zh) * 2022-11-21 2026-06-12 山东舜丰生物科技有限公司 碱基编辑工具及其应用
WO2024127370A1 (en) 2022-12-16 2024-06-20 LifeEDIT Therapeutics, Inc. Guide rnas that target trac gene and methods of use
WO2024127369A1 (en) 2022-12-16 2024-06-20 LifeEDIT Therapeutics, Inc. Guide rnas that target foxp3 gene and methods of use
WO2024178397A2 (en) 2023-02-24 2024-08-29 Elevatebio Technologies, Inc. Modified immune effector cells and methods of use
WO2024235991A1 (en) * 2023-05-15 2024-11-21 UCB Biopharma SRL Rna-guided nucleases and nucleic acid targeting systems comprising such rna-guided nucleases
WO2025003344A1 (en) * 2023-06-28 2025-01-02 Alia Therapeutics Srl Type ii cas proteins and applications thereof
EP4750890A2 (en) 2023-07-27 2026-06-03 Life Edit Therapeutics, Inc. Rna-guided nucleases and active fragments and variants thereof and methods of use
WO2025081042A1 (en) 2023-10-12 2025-04-17 Renagade Therapeutics Management Inc. Nickase-retron template-based precision editing system and methods of use
CN122422501A (zh) 2023-10-18 2026-07-17 生命编辑治疗股份有限公司 Rna引导的核酸酶及其活性片段和变体以及使用方法
WO2025155753A2 (en) 2024-01-17 2025-07-24 Renagade Therapeutics Management Inc. Improved gene editing system, guides, and methods
WO2025174908A1 (en) 2024-02-12 2025-08-21 Life Edit Therapeutics, Inc. Novel rna-guided nucleases and proteins for polymerase editing
CN120608040A (zh) * 2024-03-07 2025-09-09 清华大学 一种用于基因编辑和/或抵抗噬菌体的系统及其应用
WO2025231360A1 (en) * 2024-05-03 2025-11-06 Modernatx, Inc. Novel cas nucleases and polynucleotides encoding the same
WO2026143185A1 (en) 2024-12-23 2026-07-02 Ensoma Aps Engineered rna-guided dna-binding polypeptides

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5380831A (en) 1986-04-04 1995-01-10 Mycogen Plant Science, Inc. Synthetic insecticidal crystal protein gene
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5569597A (en) 1985-05-13 1996-10-29 Ciba Geigy Corp. Methods of inserting viral DNA into plant material
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US4853331A (en) 1985-08-16 1989-08-01 Mycogen Corporation Cloning and expression of Bacillus thuringiensis toxin gene toxic to beetles of the order Coleoptera
US5268463A (en) 1986-11-11 1993-12-07 Jefferson Richard A Plant promoter α-glucuronidase gene construct
US5608142A (en) 1986-12-03 1997-03-04 Agracetus, Inc. Insecticidal cotton plants
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5039523A (en) 1988-10-27 1991-08-13 Mycogen Corporation Novel Bacillus thuringiensis isolate denoted B.t. PS81F, active against lepidopteran pests, and a gene encoding a lepidopteran-active toxin
KR920701453A (ko) 1989-03-17 1992-08-11 미리엄 디. 멕코나헤이 유전자발현의 외부조절
ES2187497T3 (es) 1990-04-12 2003-06-16 Syngenta Participations Ag Promotores preferentemente en tejidos.
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
AU7979491A (en) 1990-05-03 1991-11-27 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5498830A (en) 1990-06-18 1996-03-12 Monsanto Company Decreased oil content in plant seeds
CA2051562C (en) 1990-10-12 2003-12-02 Jewel M. Payne Bacillus thuringiensis isolates active against dipteran pests
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5399680A (en) 1991-05-22 1995-03-21 The Salk Institute For Biological Studies Rice chitinase promoter
JPH06510187A (ja) 1991-08-27 1994-11-17 ノバルティス アクチエンゲゼルシャフト 同翅類昆虫に対する殺虫性質を有したタンパク質及び植物保護におけるそれらの用法
TW261517B (cg-RX-API-DMAC7.html) 1991-11-29 1995-11-01 Mitsubishi Shozi Kk
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
US5789156A (en) 1993-06-14 1998-08-04 Basf Ag Tetracycline-regulated transcriptional inhibitors
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5608144A (en) 1994-08-12 1997-03-04 Dna Plant Technology Corp. Plant group 2 promoters and uses thereof
US5659026A (en) 1995-03-24 1997-08-19 Pioneer Hi-Bred International ALS3 promoter
US6072050A (en) 1996-06-11 2000-06-06 Pioneer Hi-Bred International, Inc. Synthetic promoters
ES2270227T3 (es) 1998-02-26 2007-04-01 Pioneer Hi-Bred International, Inc. Promotor met-1 del maiz.
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
CN1360632A (zh) 1999-05-04 2002-07-24 孟山都技术有限公司 鞘翅目毒性多肽组合物和抗虫转基因植物
BR0014516A (pt) 1999-09-15 2002-07-02 Monsanto Technology Llc Composições e métodos de uso de delta-endotoxina do bacilo thuringiensis ativo de lepidopteran
DK2359869T3 (en) 2001-12-17 2019-04-15 Univ Pennsylvania Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof
US20050183161A1 (en) 2003-10-14 2005-08-18 Athenix Corporation AXMI-010, a delta-endotoxin gene and methods for its use
US7629504B2 (en) 2003-12-22 2009-12-08 Pioneer Hi-Bred International, Inc. Bacillus thuringiensis cry9 nucleic acids
ES2397118T3 (es) 2006-06-14 2013-03-04 Athenix Corporation AXMI-031, AXMI-039 ,AXMI-040 y AXMI-049, una familia de genes de endotoxina delta y métodos para su uso
ES2738980T3 (es) 2008-09-15 2020-01-28 Childrens Medical Ct Corp Modulación de BCL11A para el tratamiento de hemoglobinopatías
WO2010132092A2 (en) 2009-05-12 2010-11-18 The Scripps Research Institute Cytidine deaminase fusions and related methods
CN102648281B (zh) 2009-07-02 2017-04-05 阿森尼克斯公司 Axmi‑205杀虫基因和它的使用方法
US20130011380A1 (en) * 2009-12-18 2013-01-10 Blau Helen M Use of Cytidine Deaminase-Related Agents to Promote Demethylation and Cell Reprogramming
US8586832B2 (en) 2009-12-21 2013-11-19 Pioneer Hi Bred International Inc Bacillus thuringiensis gene with Lepidopteran activity
CN103154247A (zh) 2010-08-19 2013-06-12 先锋国际良种公司 对鳞翅目昆虫具有活性的新苏云金杆菌基因
US9405700B2 (en) 2010-11-04 2016-08-02 Sonics, Inc. Methods and apparatus for virtualization in an integrated circuit
JP6224689B2 (ja) * 2012-03-15 2017-11-01 ニユー・イングランド・バイオレイブス・インコーポレイテツド シトシンとこれの修飾物とを識別するための、およびメチローム分析のための方法および組成物
ES2728782T3 (es) 2012-05-25 2019-10-28 Univ California Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
HUE051612T2 (hu) 2012-07-11 2021-03-01 Sangamo Therapeutics Inc Eljárások és készítmények lizoszomális tárolási betegségek kezelésére
DK3363902T3 (da) 2012-12-06 2020-01-02 Sigma Aldrich Co Llc Crispr-baseret genommodifikation og -regulering
CN105209621B (zh) 2012-12-12 2021-05-25 布罗德研究所有限公司 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
US20150166984A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting alpha-antitrypsin point mutations
US10450584B2 (en) 2014-08-28 2019-10-22 North Carolina State University Cas9 proteins and guiding features for DNA targeting and genome editing
AU2015101792A4 (en) * 2014-12-24 2016-01-28 Massachusetts Institute Of Technology Engineering of systems, methods and optimized enzyme and guide scaffolds for sequence manipulation
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
CN116555254A (zh) 2015-10-09 2023-08-08 孟山都技术公司 新颖的rna导向性核酸酶及其用途
WO2017070632A2 (en) 2015-10-23 2017-04-27 President And Fellows Of Harvard College Nucleobase editors and uses thereof
US20190100762A1 (en) * 2016-03-11 2019-04-04 Pioneer Hi-Bred International, Inc. Novel cas9 systems and methods of use
WO2018027078A1 (en) 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof
KR20240007715A (ko) * 2016-10-14 2024-01-16 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
US20200385753A1 (en) * 2016-12-23 2020-12-10 Institute For Basic Science Composition for base editing for animal embryo and base editing method
CN110234770A (zh) * 2017-01-17 2019-09-13 基础科学研究院 通过dna单链断裂识别碱基编辑脱靶位点的方法
MX2019011215A (es) * 2017-03-24 2020-02-12 Curevac Ag Ácidos nucleicos que codifican proteínas asociadas a crispr y usos de los mismos.
EP3625342B1 (en) * 2017-05-18 2022-08-24 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
AR114014A1 (es) 2017-12-22 2020-07-08 Inst Genetics & Developmental Biology Cas Sistema de edición de bases y método basado en proteína cpf1
CN112961853B (zh) * 2018-11-02 2024-09-06 中国科学院动物研究所 基于C2c1核酸酶的基因组编辑系统和方法
CN118813654A (zh) * 2019-08-12 2024-10-22 生命编辑制药股份有限公司 Rna指导的核酸酶及其活性片段及变体以及使用方法

Also Published As

Publication number Publication date
IL312708A (en) 2024-07-01
JP2024137967A (ja) 2024-10-07
WO2020139783A2 (en) 2020-07-02
EP3902911B1 (en) 2023-12-13
ES2970169T3 (es) 2024-05-27
JP2022516130A (ja) 2022-02-24
SG11202106977PA (en) 2021-07-29
IL284400B1 (en) 2026-07-01
ZA202105281B (en) 2024-05-30
WO2020139783A3 (en) 2020-07-23
NZ778392A (en) 2025-11-28
US12188018B2 (en) 2025-01-07
US20220145296A1 (en) 2022-05-12
EP4339286A2 (en) 2024-03-20
EP3902911C0 (en) 2023-12-13
US12655426B2 (en) 2026-06-16
JP2024050676A (ja) 2024-04-10
EP3902911A2 (en) 2021-11-03
US20230272398A1 (en) 2023-08-31
TW202039847A (zh) 2020-11-01
US20250092398A1 (en) 2025-03-20
AU2019416108B2 (en) 2025-10-23
AU2019416108A1 (en) 2021-08-12
JP7572360B2 (ja) 2024-10-23
IL312708B1 (en) 2026-05-01
CN113631704A (zh) 2021-11-09
AU2025242270A1 (en) 2025-10-30
IL284400A (en) 2021-08-31
KR20210149686A (ko) 2021-12-09
BR112021012665A2 (pt) 2021-11-03
US20250066783A1 (en) 2025-02-27
EP4339286A3 (en) 2024-08-28

Similar Documents

Publication Publication Date Title
ZA202105281B (en) Polypeptides useful for gene editing and methods of use
ZA202304237B (en) Dna modifying enzymes and active fragments and variants thereof and methods of use
MX2022001849A (es) Nucleasas guiadas por acido ribonucleico (arn) y sus fragmentos activos y variantes y metodos de uso.
EP4512900A3 (en) Rna-guided nucleases and active fragments and variants thereof and methods of use
ZA202103277B (en) Programmable dna base editing by nme2cas9-deaminase fusion proteins
WO2019139645A3 (en) High efficiency base editors comprising gam
BR112022021459A2 (pt) Nucleases guiadas por rna, fragmentos ativos e variantes das mesmas e métodos de uso
EP4269577A3 (en) Nucleobase editors and uses thereof
MX2022015080A (es) Variantes de hsd17b13 y usos de las mismas.
MX2023003125A (es) Proteinas multiespecificas de union al antigeno.
MX2024009148A (es) Nucleasas guiadas por ácido ribonucleico (arn) y fragmentos y variantes activos de estas y métodos de uso
BR112018068189A2 (pt) proteínas de ligação induzíveis e métodos de uso
MX2023010640A (es) Péptidos neoantigénicos transmembranales.
BR112021007503A2 (pt) Proteína de fusão, molécula de ácido nucleico, método para edição de material genético, e, sistemas para edição de material genético e para distribuição de componentes de edição de genoma
WO2019084362A3 (en) Fusion protein and nucleic acid molecule for exogenous stimulant-dependent stress granule assembly
WO2020006131A3 (en) Nucleases for genome editing
AR125191A1 (es) Enzimas modificadoras del adn y sus fragmentos activos y variantes y métodos de uso
WO2020025953A3 (en) Nucleic acid construct
CL2025002637A1 (es) Proteínas de ingeniería y métodos de uso.
WO2016160976A3 (en) Monovalent tnf binding proteins
AR117535A1 (es) Polipéptidos útiles para edición de genes y métodos de uso
EA202191788A1 (ru) Полипептиды, применимые для редактирования генов, и способы их применения
NO20031369D0 (no) Kalium-kanal interagerende forbindelser, og anvendelser derav
AR120928A1 (es) Nucleasas guiadas por arn y sus fragmentos activos y variantes y métodos de uso
AR115486A1 (es) Nucleasas guiadas por arn y sus fragmentos activos y variantes y métodos de uso